Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
2016-000259-28Phase 3
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ibrutinib in mature B-cell neoplasm (MBCN) and mature B-cell lymphoma, sponsored by Janssen Pharmaceutical. Primary endpoint: Area Under The Plasma Concentration-Time Curve (AUC) of Ibrutinib.
02
Drugs
ibrutinib
03
Conditions
mature B-cell neoplasm (MBCN)mature B-cell lymphoma
Beyond the preview
Go deeper on 2016-000259-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000259-28.